GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (OTCPK:CLVSQ) » Definitions » EBITDA per Share

Clovis Oncology (Clovis Oncology) EBITDA per Share : $-1.52 (TTM As of Sep. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Clovis Oncology EBITDA per Share?

Clovis Oncology's EBITDA per Share for the three months ended in Sep. 2022 was $-0.31. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.52.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Clovis Oncology's EBITDA per Share or its related term are showing as below:

CLVSQ's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 6.3
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Clovis Oncology's EBITDA for the three months ended in Sep. 2022 was $-44.8 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Clovis Oncology EBITDA per Share Historical Data

The historical data trend for Clovis Oncology's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology EBITDA per Share Chart

Clovis Oncology Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.19 -6.76 -6.95 -4.01 -1.95

Clovis Oncology Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.43 -0.36 -0.42 -0.31

Clovis Oncology EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Clovis Oncology's EBITDA per Share for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA per Share(A: Dec. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=-224.759/115.528
=-1.95

Clovis Oncology's EBITDA per Share for the quarter that ended in Sep. 2022 is calculated as

EBITDA per Share(Q: Sep. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-44.794/144.625
=-0.31

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clovis Oncology  (OTCPK:CLVSQ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Clovis Oncology EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Clovis Oncology (Clovis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
Thomas C. Harding officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Gillian C Ivers-read officer: See Remarks C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Lindsey Rolfe officer: See remarks C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Daniel W Muehl officer: See remarks 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862
Paul Edward Gross officer: See Remarks 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302
Ronit Simantov director 1988 CHAPEL STREET, NEW HAVEN CT 06515
James C Blair director 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Patrick J Mahaffy director, officer: President and CEO C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Thorlef Spickschen director TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000
Richard A. Fair director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Hooks Corwin Dale officer: See remarks C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
Ginger L Graham director AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

Clovis Oncology (Clovis Oncology) Headlines

From GuruFocus

Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

By Business Wire Business Wire 07-12-2021

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

By Business Wire Business Wire 10-19-2021